CC BY
0EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
QALQONSIMON BEZ SARATONI ZAMONAVIY INSTRUMENTAL TASHXISLASH USULLARI
Zaretdinov Damir Arifovich
t.f.d., professor, O'zbekiston Respublikasi bosh radiologi, ToshTHKMPM radiatsion gigiena bo'limi mudiri Alimdjonov Nusratjon Amildjonovich t.f.n.,
akademik Y.X. To'raqulov nomidagi RIEIATM
bo'lim mudiri Nurmuhamedov Doniyorbek Baxtiyorovich akademik Y.X. To'raqulov nomidagi RIEIATM radiolog shifokori Omiljonov Murodjon Nusratjonovich akademik Y.X. To'raqulov nomidagi RIEIATM endokrin jarrox shifokori https://www.doi.org/10.5281/zenodo.10574615
ABSTRACT
ARTICLE INFO
Received: 19th January 2024 Accepted: 26th January 2024 Online: 27th January 2024
KEY WORDS Qalqonsimon bez saratoni, ultratovush tekshiruvi, magnit-rezonans tomografiya, bir fotonli emission kompyuter tomografiya.
Ushbu tadqiqot qalqonsimon bez saratonini instrumental tekshiruvlar orqali tashxislash va ularning samaradorligini baholashdan iborat. Bu yerda akademik Y.X.To'raqulov nomidagi RIEIAT markazida UTT, MRT va OFEKT/KT yordamida ularning qalqonsimon bez diagnostikasida tutgan o'rni, afzalliklari va kamchiliklari o'rganildi.
Tadqiqot maqsadi: qalqonsimon bez saratonida instrumental usullar orqali tashxislash usullari samaradorligini baxolash
Material uslublar: akademik Y.X. To'raqulov nomidagi RIEIATM da tugunli bo'qoq bilan murojaat qilgan bemorlarga jarroxlik amaliyotidan oldin ultratovush tekshiruvi (UTT), magnit rezonans tomografiya (MRT) va bir fotonli emission kompyuter tomogragiya (OFEKT/KT) tekshiruvlari o'tkazildi. Xar birining diagnostik ahamiyati baxolandi va xulosalar qayd etildi.
Natijalar va muxokama: UTT boshqa usullarga qaraganda tugunli qalqonsimon bez kasalligini baxolash uchun sezgir va oziga xosdir. UTT qalqonsimon bez va bo'yin limfa tugunlarida shubha bo'lgan barcha kasalliklarda yoki tasodifan aniqlangan tugunli xolatlarda o'tkazilishi shart.
KIRISH
Qalqonsimon bez tabaqalanuvchi saratoni global eng keng tarqalgan endokrin va bosh-bo'yin sohalaridagi saratonlardan biri bo'lib xisoblanadi. 1990-yillardan boshlab kasallikning tarqalish darajasi cheklangan diagnostika texnologiyalari sabablari Afrikadan tashqari butun dunyoda tez sur'atlar bilan o'sib bordi. Paes va boshq. 2010 yildagi taxlillari natijasida, qalqonsimon bez saratoni, boshqa saraton kasalliklari ichida tez suratlarda o'sib borayotganini aniqladilar (1). Saraton tadqiqotlari agentligidan (GLOBOCAN) 2018 yildagi ma'lumotlarga ko'ra, taxminan 567,200 yangi holatlar va 41,100 o'lim holatlarga (2)
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
qalqonsimon bez saratoni sabab bo'ladi. Osiyoda qalqonsimon bez saratoni bilan kasallanish darajasi ham ortib bormoqda. Osiyo saraton ro'yxatga olish reestrining 2018 yilgi holatiga ko'ra, sog'liqqa tahdid qilishi mumkin bo'lgan 3 yirik saraton kasalliklaridan biri bo'ldi. Ba'zi Osiyo davlatlarida (Xitoy, Qirg'iziston, Qozog'iston) qalqonsimon bez saratoni bilan kasallanish darajasi ayollarda (4) keskin yuqoriga ko'tarildi. Umummilliy malumotlarning olish uchun ma'lumot olish masalasi (5-7) qalqonsimon bez saraton kasalligi va o'lim holatlari haqida ma'lumot olishga to'g'ri keladi. Saraton bilan kasallanish darajasini aniqlashga AQSh Milliy reestri Osiyo davlatlari haqida bir ma'lumot taqdim etmaydi.
Qalqonsimon bez saratonining turlari
Qalqonsimon bez papillyar saratoni (QBPS), qalqonsimon bez follikulyar saratoni (QBFS), qalqonsimon bez anaplastik saratoni (QBAS) va medullyar qalqonsimon bez sartonlari (QBMS) farqlanadi (1). Qalqonsimon bez yuqori tabaqalanuvchi saratoniga - QBPS, QBFS va QBMS kiradi, kam va tabaqalanmaydigan turlarga QBAS kiradi. Yuqori tabaqalanuvchi qalqonsimon bez saratoni umumiy qalqonsimon bez saratonining tahminan 95% ni tashkil qilib (1), QBPS va QBFS boshqa turlarga qaraganda yaxshiroq prognozga ega. Qalqonsimon bez saratonini rivojlanishida radiatsiya, irsiyat va boshqa omillar o'rin egallaydi. QBS limfa tugunlariga limfa yo'llari orqali, suyak va boshqa a'zolarga gematogen - qon tomirlar orqali tarqaladi (2). QBMS qalqonsimon bezning parafollikulyar neyroendokrin hujayralaridan rivojlanadi va ko'pincha bo'yin limfa tugunlariga metastaz beradi (2). Qalqonsimon bez saratonining kichik tiplari va metastazning umumiy yo'llarining yo'nalishlari bo'yicha xatti-harakatlarini bilish diagnostika va davolash strategiyasining ajralmas qismidir.
Qalqonsimon bezni ultratovush tekshiruvi
• UTT tugunli qalqonsimon bez kasalligini baxolash uchun palpatsiyaga qaraganda sezgir va o'ziga xosdir (2,3).
• UTT qalqonsimon bez va buyin limfa tugunlarida shubha qilingan barcha kasalliklarda yoki tasodifan aniqlangan tugunli xolatlarda o'tkazilishi shart (3).
TIRADS ballari UTT da qalqonsimon bezdagi tugunlar, ularni ta'riflash va xavflilik darajasi aniqlash uchun ishlab chiqilgan, bunda kerak bo'lmagan biopsiya va sitologik tekshirishlarni oldini oladi. Shuningdek, butun dunyodagi shifokorlar fikrini bir erga jamlash, ularni o'zaro bir to'xtamga kelishlari va bemorlarga to'g'ri yordam ko'rsatishlari uchun qo'llaniladi. Buning uchun qalqonsimon bez tugunlarini UTT ga asoslangan xolda TIRADS tizimida 5 daraja ishlab chiqarilgan, ular natijasida qolgan qalqonsimon bezni sitologik tekshirishlarga o'z vaqtida yordam berishga xizmat qiladi. TIRADS tizimidagi 5 daraja QBPS tashxislashda ijobiy natijalar beradi, lekin QBFS va QBMS da qiyinchiliklarga duch keladi (4,5).
1-jadval: qalqonsimon bez tugunli kasalliklarida UTT ning xisobot ko'rsatkichlari.
Qalqonsimon bez toqimasi ■ Exogenlik ■ Hajmi (uch o'lchamda va maydoni) ■ Qalqonsimon bez bo'yin qismining kengayishi yoki kichrayishi
Tugun ■ Kattaligi (uch o'lcham va maydonda) ■ Siqilish ■ Exogenlik
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
■ Tarkibi ■ Mavjud shubhali belgilar1 ■ Qalqonsimon bezdan tashqari kattalashish belgilari
Qaysi aloxida zararlangan soxalarni tavsiflash lozim? ■ 10 mm dan katta bulgan tugunlar ■ Shubxali 5-10 mm o'lchamdagi tugunlar
Qancha tugunlarni batafsil tavsiflash kerak? ■ Tekshirish vaqtida tugunlar soni >3 bo'lsa, eng kattasi va shaxsiy belgilarga tegishli bo'lgan xolatlarni tavsiflash kerak2
Mavjud patologik limfa tugunlar ■ Joylashuvi, uchta o'lchami, belgilari
1 - shubxali ultratovush belgilari: mikrokaltsifikatlar, noaniq va notesiks chegaralar, gipoehogenlik. Shubhali bo'lmagan ultratovush belgilari: ingichka Galo, makrokaltsifikatsiya.
2 - bemorlarga jarroxlik amaliyoti paytida sifatli yordam berilmoqda.
2-jadval: EU-TIRADS darajalariga qarab qalqonsimon bez xavfsiz tugunlarini aniqlash va ularni tegishli tartibida sitologik tekshiruvga yo'naltirish.
Kategoriya 1 UTT xususiyatlari Xavf-xatarlilik darajasi (%) Jarrohlik amaliyotiga nisbatan kuzatilgan xavf darajasi Sitologik tekshiruv2
EU-TIRADS 1 normal tugunlar yo'q - - y°'q
EU-TIRADS 2 xavfsiz kista gubka ko'rinishida 0 1.4 y°'q
EU-TIRADS 3 past xavf Izo/giperexogen yuqori xavf belgilari mavjud emas 2-4 3.5 >20 mm
EU-TIRADS 4 o'rta xavf kam gipoexogen yuqori xavf belgilari mavjud emas 6-17 17 >15 mm
EU-TIRADS 5 yuqori xavf Quyidagi belgilardan 1 mavjud bo'lsa: ■ Noto'g'ri shakll ■ Geterogen tarkib ■ Mikrokaltsifikatsiya ■ Yuqori gipoexogenlik 26-87 87.7 >10 мм3
1. Xavflilik darajasi soniga qarab, biz ushbu tugunlarni EU-TIRADS 4 deb tasniflashni taklif qilamiz.
2. Agar patologik limfa tugunlari mavjud bo'lsa yoki tugun qalqonsimon bezdan
tashqariga o'sishiga shubxa bo'lsa, sitologik tekhiruv EU-TIRADS darajasidan qat'iy nazar barcha xolatlarda bajarilishi kerak.
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
3. 5-10 mm mahalliy kattalashgan limfatik tug'unlar mavjud bo'lgan xolatlarda yoki tugunlarni qalqonsimon bezdan tashqariga o'sish belgilari aniqlansa, sitologik tekshirishuv qilinishi kerak.
Aniq bir davolash tadbirlari amalga oshirilmaganda, tugunlarni nazorat qilish tartibi:
■ Tugunlarni kattalashishini nazorat qilish (ikki o'lchamda >20% kattalashsa yoki qayta ko'rish vaqtida >50% kattalashsa).
■ UTT da qalqonsimon bez va uni tugunlarini exo-belgilarini baxolash.
■ Bo'yin limfa tug'unlar monitoringi.
■ Maxalliy bosim paydo bo'lishi va/yoki ovoz tembrining o'zgarishi mavjud bo'lsa, qayta tekshirish.
2-rasm: qalqonsimon bez saratoni OFEKT-KT tekshiruvida.
à L A À
4 ♦
Qalqonsimon bez OFEKT tekshiruvi
WO
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
Bu tekshiruv 2 qismdan tashkil topgan, birinchisi qalqonsimon bez sintigrafiyasi va ikkinchisi qalqonsimon bez KT tekshiruvi. Bu ikkala tekshiruv bir joyda jamlanib juda katta funksional - anatomik ma'lumotlarni taqdim etadi.
Qalqonsimon bez sintigrafiya tekshiruvi qalqonsimon bez va tugunlarni metabolik faoliyatini baholashga imkon beradi (23,24). Ko'pincha Tc-99m izotopi qo'llaniladi, bu arzon, tez va past radiatsiya yuklanishiga ega bo'ladi. Qalqonsimon bez sintigrafiya tekshiruvi TTG pastki normal chegaralarda bo'lganda foydalanish tavsiya etiladi. So'ngi yillarda, normal TTG bo'lgan insonlarda giperfunksiyaga ega bo'lgan tugunlari ham kuzatish mumkin (42,43). Qalqonsimon bez sintigrafiya tekshiruvini Tc99-MIBI bilan o'tkazishni tavsiya etmaymiz. 18-FDG PET tekshiruvi aniq to'xtamga kelmagan va noaniq taxlillar paytida tavsiya etiladi. KT tekshiruvda - qalqonsimon bezning anatomik xolati, tugunlarning yaxlit kesimda joylashganligi, ekstratireoid tarqalish, atrof to'qimalar - hiqildoq, qizilo'ngach, mushaklar, bo'yin va to'sh orti sohalari tomon o'sishi, limfatik tugunlar xolati haqida ma'lumot olish mumkin.
Qalqonsimon bezni I-131 bilan OFEKT/KT tekshiruvi noaniq yoki shubxali tugunlarni aniqlash uchun xizmat qiladi. Tireosit xujayralarning bazal membranasida yod simporterlari I-131 iztopini qabul qilish uchun xizmat qilib, davolash choralariga yordam beradi. I-131 izotopini tugunlarda ko'p to'planishi - "issiq", aksincha kam to'planishi "sovuq" o'choqlar deb nomlanadi. I-131 OFEKT/KT tekshiruvi jarroxlik jarayonidan keyingi qalqonsimon bez saratoni qo'ldiq to'qimalarini aniqlash, ularni xajmi, kattaligi va anatomik xususiyatlarini baholash, zararlangan ikkilamchi patologik o'choqlar - metastazlarni to'pishga imkon beradi. Bundan tashqari, oldingi I-131 terapiya samarasini baxolashga yordam beradi.
3-rasm: qalqonsimon bez saratoni I-131 terapiyadan keyingi holat (metabolik faol saraton qo'ldiq to'qimasi va zararlangan limfatik tugunlar).
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
Qalqonsimon bez MRT tekshiruvi
Boshqa usullar bilan taqqoslaganda MRT ikkinchi holatida qo'llaniladi. UTT qalqonsimon bez saratonida dastlabki tashxis qo'yish va keyingi baholash uchun tanlov usuli hisoblanadi. MRT tekshiruvida boshqa instrumental tekshiruvlarga nisbatan bo'yin soxasi yumshoq to'qimalarni baxolash foizi yuqoriroq bo'lib xisoblanadi. Yangi MRT texnologiyasi kontrast yordamida yumshoq to'qimalarining o'simta darajasini va atrofdagi to'qimalarning infiltratsiyasini (tomirlar, nervlar, suyaklar va boshqalar) aniqroq baholaydi.
2-rasm: qalqonsimon bez saratoni MRT tekshiruvida.
XULOSA
Qalqonsimon bez saratonining tarqalishi oshgani sayin, qalqonsimon bez tugunli kasalliklarini o'z vaqtida aniqlash davolash sifatini yaxshilash uchun zarurdir. Tasviriy tashxis qo'yish usullari qalqonsimon bez saratonini aniqlash va kuzatish uchun ajralmas usullardan bo'lib xisoblanadi, UTT qalqonsimon bez va uning tugunlarini baholashni asosiy tanlov usuli bo'lib xisoblanadi. Ko'rsatmalarga ko'ra, noaniq tugunli xosilalarda OFEKT/KT yoki sitologiya tekshiruvlari o'tkazilishi mumkin. KT tekshiruvi tugunlarni ekstratiroid tarqalishi va metastazlarni aniqlashda yordam beradi. MRT kontrast tekshiruvi qalqonsimon bez saratonini yumshoq to'qimalarga tarqalishini aniqlash uchun xizmat ko'rsatadi, jarroxlik amaliyotidan keyingi xolatni baxolash uchun xizmat qiladi. O'n yil davomida I-131 bilan xam diagnostika xam davolash maqsadida foydalanilgan. FDA (Amerika ozik-ovqatlar sifatni nazorat qilish departamenti) so'ngi yillarda birlamchi o'smalarni davolashda ishlab chiqariladigan va samarasi yuqori bo'lgan yangi izotoplarni ishlab chiqarishi kutilmoqda.
References:
1. Shore SL. Thyroid Cancer. In: Vinjamuri S, editor. PET/CT in Thyroid Cancer. Cham: Springer International Publishing; 2018. p. 1-7. [Google Scholar]
2. Shore SL. Thyroid Cancer Pathology. In: Vinjamuri S, editor. PET/CT in Thyroid Cancer. Cham: Springer International Publishing; 2018. p. 9-13. [Google Scholar]
3. Haymart MR, Banerjee M, Reyes-Gastelum D, et al. Thyroid Ultrasound and the Increase in Diagnosis of Low-Risk Thyroid Cancer. J Clin Endocrinol Metab 2019;104:785-92. 10.1210/jc.2018-01933 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
4. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016;12:646-53. 10.1038/nrendo.2016.110 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017;317:1338-48. 10.1001/jama.2017.2719 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Lubitz CC, Sosa JA. The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer 2016;122:3754-9. 10.1002/cncr.30201 [PubMed] [CrossRef] [Google Scholar]
7. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-80. 10.1038/nrendo.2011.142 [PubMed] [CrossRef] [Google Scholar]
8. Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer2014;120:3627-34. 10.1002/cncr.29038 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010;95:5296-304. 10.1210/jc.2010-1087 [PubMed] [CrossRef] [Google Scholar]
10. Wylie D, Beaudenon-Huibregtse S, Haynes BC, et al. Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations. J Pathol Clin Res 2016;2:93-103. 10.1002/cjp2.38 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Sandler JE, Huang H, Zhao N, et al. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev 2018;27:285-94. 10.1158/1055-9965.EPI-17-0319 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Lew JI, Solorzano CC. Use of ultrasound in the management of thyroid
cancer. Oncologist 2010;15:253-8. 10.1634/theoncologist.2009-0324 [PMC_free
article] [PubMed] [CrossRef] [Google Scholar]
13. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017;27:1341-6. 10.1089/thy.2017.0500 [PubMed] [CrossRef] [Google Scholar]
14. Wu Y, Xu T, Cao X, et al. BRAF (V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules. Cancer Biol Med 2019;16:131-8. 10.20892/j.issn.2095-3941.2018.0291 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Zhu J, Li X, Wei X, et al. The application value of modified thyroid imaging report and data system in diagnosing medullary thyroid carcinoma. Cancer Med 2019;8:3389-400. 10.1002/cam4.2217 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Grant EG, Tessler FN, Hoang JK, et al. Thyroid Ultrasound Reporting Lexicon: White Paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. J Am Coll Radiol 2015;12:1272-9. 10.1016/j.jacr.2015.07.011 [PubMed] [CrossRef] [Google Scholar]
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
17. Tessler FN, Middleton WD, Grant EG. Thyroid Imaging Reporting and Data System (TI-RADS): A User's Guide. Radiology 2018;287:29-36. 10.1148/radiol.2017171240 [PubMed] [CrossRef] [Google Scholar]
18. Persichetti A, Di Stasio E, Guglielmi R, et al. Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems: A Prospective Study. J Clin Endocrinol Metab 2018;103:1359-68. 10.1210/jc.2017-01708 [PubMed] [CrossRef] [Google Scholar]
19. Ram N, Hafeez S, Qamar S, et al. Diagnostic validity of ultrasonography in thyroid nodules. J Pak Med Assoc 2015;65:875-8. [PubMed] [Google Scholar]
20. Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:1253-63. 10.1210/jc.2013-2928 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Chudgar AV, Shah JC. Pictorial Review of False-Positive Results on Radioiodine Scintigrams of Patients with Differentiated Thyroid Cancer. Radiographics 2017;37:298-315. 10.1148/rg.2017160074 [PubMed] [CrossRef] [Google Scholar]
22. Xue YL, Qiu ZL, Perotti G, et al. 131I SPECT/CT: a one-station imaging modality in the management of differentiated thyroid cancer. Clinical and Translational Imaging 2013;1:163-73. 10.1007/s40336-013-0020-4 [CrossRef] [Google Scholar]
23. Ahmed S, Horton KM, Jeffrey RB, Jr, et al. Incidental thyroid nodules on chest CT: Review of the literature and management suggestions. AJR Am J Roentgenol 2010;195:1066-71. 10.2214/AJR.10.4506 [PubMed] [CrossRef] [Google Scholar]
24. Hoang JK, Langer JE, Middleton WD, et al. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol 2015;12:143-50. 10.1016/j.jacr.2014.09.038 [PubMed] [CrossRef] [Google Scholar]
25. Abraham T, Schoder H. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 2011;41:121-38. 10.1053/j.semnuclmed.2010.10.006 [PubMed] [CrossRef] [Google Scholar]
26. Ciarallo A, Marcus C, Taghipour M, et al. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clin 2015;10:265-78. 10.1016/j.cpet.2014.12.009 [PubMed] [CrossRef] [Google Scholar]
27. Song B, Wang H, Chen Y, et al. Magnetic resonance imaging in the prediction of aggressive histological features in papillary thyroid carcinoma. Medicine (Baltimore) 2018;97:e11279. 10.1097/MD.0000000000011279 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Noda Y, Kanematsu M, Goshima S, et al. MRI of the thyroid for differential diagnosis of benign thyroid nodules and papillary carcinomas. AJR Am J Roentgenol 2015;204:W332-5. 10.2214/AJR.14.13344 [PubMed] [CrossRef] [Google Scholar]
29. Yuan Y, Yue XH, Tao XF. The diagnostic value of dynamic contrast-enhanced MRI for thyroid tumors. Eur J Radiol 2012;81:3313-8. 10.1016/j.ejrad.2012.04.029 [PubMed] [CrossRef] [Google Scholar]
30. Varoquaux A, Rager O, Dulguerov P, et al. Diffusion-weighted and PET/MR Imaging after Radiation Therapy for Malignant Head and Neck Tumors. Radiographics 2015;35:1502-27. 10.1148/rg.2015140029 [PubMed] [CrossRef] [Google Scholar]
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
31. Binse I, Poeppel TD, Ruhlmann M, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging 2016;43:1011-7. 10.1007/s00259-015-3288-y [PubMed] [CrossRef] [Google Scholar]
32. Jentzen W, Phaosricharoen J, Gomez B, et al. Quantitative performance of (124)I PET/MR of neck lesions in thyroid cancer patients using (124)I PET/CT as reference. EJNMMI Phys 2018;5:13. 10.1186/s40658-018-0214-y [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Jadvar H, Chen X, Cai W, et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018;286:388-400. 10.1148/radiol.2017170346 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
34. Budiawan H, Salavati A, Kulkarni HR, et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2013;4:39-52. [PMC free article] [PubMed] [Google Scholar]
35. Santhanam P, Solnes LB, Rowe SP. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Med Oncol 2017;34:189. 10.1007/s12032-017-1051-x [PubMed] [CrossRef] [Google Scholar]
36. Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009;72:217-38. 10.1016/j.critrevonc.2008.07.012 [PubMed] [CrossRef] [Google Scholar]
37. Lalchandani UR, Sahai V, Hersberger K, et al. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. Curr Probl Diagn Radiol 2019;48:576-85. 10.1067/j.cpradiol.2018.07.016 [PubMed] [CrossRef] [Google Scholar]
38. Gilardi L, Grana CM, Paganelli G. Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. European Journal of Nuclear Medicine and Molecular Imaging 2014;41:2090-2. 10.1007/s00259-014-2848-x [PubMed] [CrossRef] [Google Scholar]
39. Kim HD, Kim BJ, Kim HS, et al. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. Korean J Intern Med 2019;34:608-17. 10.3904/kjim.2017.063 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
40. O JH , Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576-84. 10.1148/radiol.2016142043 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Min SJ, Jang HJ, Kim JH. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget 2016;7:27848-54. 10.18632/oncotarget.8425 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. O JH , Wahl RL. PERCIST in Perspective. Nucl Med Mol Imaging 2018;52:1-4. 10.1007/s13139-017-0507-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Aras M, Erdil TY, Dane F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med
EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center UIF = 8.3 | SJIF = 5.995 www.in-academy.uz
Commun 2016;37:9-15. 10.1097/MNM.0000000000000401 [PubMed] [CrossRef] [Google Scholar]
